Outlook Therapeutics, Inc. (NASDAQ: OTLK) is a Healthcare company (Biotechnology) with a market capitalization of $88M. The Maz Rating grades it against the other companies in its sector.
Outlook Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
Outlook Therapeutics, Inc. has been loss-making over the last twelve months, so it has no meaningful P/E. It runs an operating margin of 4783.1% and a net margin of 5254.8%. It shows return on equity of 222.0%, return on invested capital of -343.7% and a free cash flow yield of -65.1%. On the balance sheet: a debt-to-equity ratio of -1.77 and a current ratio of 0.81. Over the past 52 weeks the share price ranged from $0.16 to $2.54, with a beta of 0.71.
Outlook Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 8 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.